FDA warns against popular anti-obesity drugs; including one Musk admitted taking
The FDA has mandated that manufacturers of popular GLP-1 anti-obesity drugs, such as Ozempic and Wegovy, add warnings regarding a potential risk of a rare eye condition called NAION. This condition can lead to permanent vision loss, though the causal link remains under investigation.
Why it matters
As these drugs gain widespread popularity for weight loss, identifying potential long-term side effects is critical for public health safety.
America's Food and Drug Administration (FDA) is warning that popular obesity drugs, including Ozempic, Wegovy, Zepbound, and Mounjaro, may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss. For those unaware, Mounjaro, Ozempic and Wegovy are all part of a buzzy class of drugs known as GLP-1 agonists, which are seen as potential game-changers for patients struggling with obesity and diabetes.In a recent drug safety communication, the FDA said that it will now require makers of GLP-1 receptor agonist drugs to add a warning about that risk on their drug labels. As per the advisory, "The US Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in